Publications by authors named "Veronica Lepechkin-Zilbermintz"
Article Synopsis
- Since the 1950s, AMPK has been a key target for developing drugs to treat Type 2 diabetes, with metformin being a notable example that activates AMPK.
- Researchers designed and synthesized 20 new cyclic and acyclic dithioacetals aimed at enhancing AMPK activation, finding that three compounds significantly improved glucose uptake in rat muscle cells.
- One of these compounds, 4-(6-(1,3-dithian-2-yl)chroman-2-yl)pyridine, not only increased glucose uptake but also boosted insulin secretion, showing strong potential for a new class of antidiabetic drugs with combined effects for managing Type 2 diabetes.
Development and characterisation of SMURF2-targeting modifiers.
J Enzyme Inhib Med Chem
December 2021
The C2-WW-HECT-domain E3 ubiquitin ligase SMURF2 emerges as an important regulator of diverse cellular processes. To date, SMURF2-specific modulators were not developed. Here, we generated and investigated a set of SMURF2-targeting synthetic peptides and peptidomimetics designed to stimulate SMURF2's autoubiquitination and turnover via a disruption of the inhibitory intramolecular interaction between its C2 and HECT domains.
View Article and Find Full Text PDFFive out of six people receive at least one antibiotic prescription per year. However, the ever-expanding use of antibiotics in medicine, agriculture, and food production has accelerated the evolution of antibiotic-resistant bacteria, which, in turn, made the development of novel antibiotics based on new molecular targets a priority in medicinal chemistry. One way of possibly combatting resistant bacterial infections is by inhibiting the copper transporters in prokaryotic cells.
View Article and Find Full Text PDF